Eastman Chemical Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
Eastman Chemical wird ein jährliches Gewinn- und Umsatzwachstum von 7.7% bzw. 4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 17.1% betragen.
Wichtige Informationen
8.9%
Wachstumsrate der Gewinne
9.4%
EPS-Wachstumsrate
| Chemicals Gewinnwachstum | 17.9% |
| Wachstumsrate der Einnahmen | 3.9% |
| Zukünftige Eigenkapitalrendite | 16.8% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 16 Aug 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Is Eastman Chemical (NYSE:EMN) Using Too Much Debt?
Sep 08
We Ran A Stock Scan For Earnings Growth And Eastman Chemical (NYSE:EMN) Passed With Ease
Aug 15Eastman Chemical Company (NYSE:EMN) Shares Could Be 33% Below Their Intrinsic Value Estimate
Jul 28Eastman Chemical Company's (NYSE:EMN) Share Price Is Matching Sentiment Around Its Earnings
Jul 16Eastman Chemical Running In Place (Rating Downgrade)
Jul 10Is Now An Opportune Moment To Examine Eastman Chemical Company (NYSE:EMN)?
Jun 03Does Eastman Chemical (NYSE:EMN) Have A Healthy Balance Sheet?
May 08It's Probably Less Likely That Eastman Chemical Company's (NYSE:EMN) CEO Will See A Huge Pay Rise This Year
Apr 26Eastman Chemical: Cyclical But Resilient
Apr 25Eastman Chemical Company's (NYSE:EMN) Share Price Is Matching Sentiment Around Its Earnings
Apr 03Is There An Opportunity With Eastman Chemical Company's (NYSE:EMN) 22% Undervaluation?
Feb 22We Think You Should Be Aware Of Some Concerning Factors In Eastman Chemical's (NYSE:EMN) Earnings
Feb 09Here's Why Eastman Chemical (NYSE:EMN) Has A Meaningful Debt Burden
Jan 23Eastman Chemical Company (NYSE:EMN) Screens Well But There Might Be A Catch
Jan 02Eastman Chemical's (NYSE:EMN) Shareholders Will Receive A Bigger Dividend Than Last Year
Dec 13Eastman Chemical: Structural Disappointments
Nov 22Is There Now An Opportunity In Eastman Chemical Company (NYSE:EMN)?
Nov 08Eastman Chemical: Shares Are Already Pricing In Recovery
Nov 01These 4 Measures Indicate That Eastman Chemical (NYSE:EMN) Is Using Debt Extensively
Oct 24Eastman Chemical: Sales Volumes Need To Stabilize
Sep 18Eastman Chemical Company (NYSE:EMN) Shares Could Be 37% Below Their Intrinsic Value Estimate
Sep 17Is It Time To Consider Buying Eastman Chemical Company (NYSE:EMN)?
Jul 27Is Eastman Chemical (NYSE:EMN) Using Too Much Debt?
Jul 12Eastman Chemical Benefits From Reversal In Gas And NGL Costs
Jul 03Eastman Chemical Company's (NYSE:EMN) Intrinsic Value Is Potentially 42% Above Its Share Price
Jun 073 Reasons To Consider Eastman Chemical Company
May 30At US$81.79, Is It Time To Put Eastman Chemical Company (NYSE:EMN) On Your Watch List?
Apr 21Here's Why Eastman Chemical (NYSE:EMN) Has A Meaningful Debt Burden
Apr 06Are Investors Undervaluing Eastman Chemical Company (NYSE:EMN) By 28%?
Mar 06Eastman Chemical: A Sporty Valuation But A Bearish Chart Post-Earnings
Feb 26Should You Think About Buying Eastman Chemical Company (NYSE:EMN) Now?
Jan 09Here's Why Eastman Chemical (NYSE:EMN) Can Manage Its Debt Responsibly
Dec 28Eastman Chemical (NYSE:EMN) Is Experiencing Growth In Returns On Capital
Dec 16Eastman Chemical: A Great Long-Term Dividend Stock At The Right Price
Dec 13Eastman Chemical (NYSE:EMN) Is Paying Out A Larger Dividend Than Last Year
Dec 05Does Eastman Chemical (NYSE:EMN) Deserve A Spot On Your Watchlist?
Nov 21Eastman Chemical Non-GAAP EPS of $2.05 beats by $0.05, revenue of $2.71B beats by $140M
Oct 27Is Eastman Chemical Company (NYSE:EMN) Trading At A 41% Discount?
Oct 23Eastman Chemical Company: An Underappreciated ESG Investment
Oct 20While Beaten Down, Eastman Shares Still Have Downside
Oct 11Eastman to provide Ethicon with medical-grade materials for product packaging
Sep 20Here's Why Eastman Chemical (NYSE:EMN) Can Manage Its Debt Responsibly
Sep 15Eastman Chemical slides as Q3 earnings outlook falls short
Sep 13Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 10,407 | 1,070 | 871 | 1,607 | 10 |
| 12/31/2025 | 9,780 | 1,021 | 638 | 1,465 | 17 |
| 12/31/2024 | 9,324 | 862 | 677 | 1,380 | 17 |
| 6/30/2024 | 9,147 | 883 | 598 | 1,317 | N/A |
| 3/31/2024 | 9,108 | 925 | 517 | 1,360 | N/A |
| 12/31/2023 | 9,210 | 894 | 541 | 1,374 | N/A |
| 9/30/2023 | 9,376 | 585 | 520 | 1,379 | N/A |
| 6/30/2023 | 9,818 | 708 | 334 | 1,121 | N/A |
| 3/31/2023 | 10,278 | 692 | 271 | 956 | N/A |
| 12/31/2022 | 10,580 | 793 | 351 | 975 | N/A |
| 9/30/2022 | 10,901 | 1,170 | 285 | 948 | N/A |
| 6/30/2022 | 10,912 | 1,220 | 617 | 1,239 | N/A |
| 3/31/2022 | 10,781 | 818 | 824 | 1,420 | N/A |
| 12/31/2021 | 10,476 | 857 | 1,041 | 1,619 | N/A |
| 9/30/2021 | 9,968 | 511 | 1,144 | 1,595 | N/A |
| 6/30/2021 | 9,370 | 321 | 1,084 | 1,490 | N/A |
| 3/31/2021 | 8,641 | 494 | 1,108 | 1,500 | N/A |
| 12/31/2020 | 8,473 | 478 | 1,059 | 1,455 | N/A |
| 9/30/2020 | 8,492 | 472 | 1,325 | 1,720 | N/A |
| 6/30/2020 | 8,695 | 577 | 1,267 | 1,694 | N/A |
| 3/31/2020 | 9,134 | 808 | 1,260 | 1,680 | N/A |
| 12/31/2019 | 9,273 | 759 | 1,073 | 1,504 | N/A |
| 9/30/2019 | 9,444 | 767 | 1,118 | 1,573 | N/A |
| 6/30/2019 | 9,666 | 913 | 1,070 | 1,552 | N/A |
| 3/31/2019 | 9,924 | 999 | 1,067 | 1,573 | N/A |
| 12/31/2018 | 10,151 | 1,080 | 1,015 | 1,543 | N/A |
| 9/30/2018 | 10,137 | 1,537 | 857 | 1,449 | N/A |
| 6/30/2018 | 10,055 | 1,448 | 968 | 1,582 | N/A |
| 3/31/2018 | 9,853 | 1,396 | N/A | 1,570 | N/A |
| 12/31/2017 | 9,549 | 1,384 | N/A | 1,657 | N/A |
| 9/30/2017 | 9,375 | 1,009 | N/A | 1,401 | N/A |
| 6/30/2017 | 9,197 | 918 | N/A | 1,323 | N/A |
| 3/31/2017 | 9,075 | 881 | N/A | 1,386 | N/A |
| 12/31/2016 | 9,008 | 854 | N/A | 1,385 | N/A |
| 9/30/2016 | 9,045 | 862 | N/A | 1,569 | N/A |
| 6/30/2016 | 9,205 | 886 | N/A | 1,487 | N/A |
| 3/31/2016 | 9,441 | 928 | N/A | 1,584 | N/A |
| 12/31/2015 | 9,648 | 848 | N/A | 1,624 | N/A |
| 9/30/2015 | 9,772 | 740 | N/A | 1,509 | N/A |
| 6/30/2015 | 9,738 | 694 | N/A | 1,701 | N/A |
| 3/31/2015 | 9,665 | 687 | N/A | 1,529 | N/A |
| 12/31/2014 | 9,527 | 749 | N/A | 1,433 | N/A |
| 9/30/2014 | 9,443 | 1,079 | N/A | 1,452 | N/A |
| 6/30/2014 | 9,368 | 1,177 | N/A | 1,319 | N/A |
| 3/31/2014 | 9,348 | 1,151 | N/A | 1,262 | N/A |
| 12/31/2013 | 9,350 | 1,165 | N/A | 1,297 | N/A |
| 9/30/2013 | 9,254 | 765 | N/A | 1,234 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: EMNDas prognostizierte Gewinnwachstum (7.7% pro Jahr) liegt über der Sparquote (2.4%).
Ertrag vs. Markt: EMNDie Erträge des Unternehmens (7.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (14.8% pro Jahr).
Hohe Wachstumserträge: EMNDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: EMNDie Einnahmen des Unternehmens (4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).
Hohe Wachstumseinnahmen: EMNDie Einnahmen des Unternehmens (4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: EMNDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (17.1%).